Compare DexCom, Inc. (DXCM) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Manhattan Associates Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Manhattan Associates Inc trades at $204.89 (market cap $12.06B). The key difference: DexCom, Inc. is far larger — about 2.6× Manhattan Associates Inc's market cap, and Manhattan Associates Inc is more actively traded (376,150 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Manhattan Associates Inc for 12 Days on average.
| DXCM | MANH | |
|---|---|---|
Market Cap | $31.86B | $12.06B |
Volume | 3,607,070 | 376,150 |
Sector | Health | Technology |
52-Week High | $92.34 | $223.76 |
52-Week Low | $54.84 | $120.88 |
Typical Hold Time | 62 Days | 12 Days |
Enterprise Value | $31.32B | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MANH trades at $206.78, up 2.31% today, near its consensus price target of $210.50. The stock shows strong profitability with a net margin of 18.67% and has beaten earnings estimates for the last three quarters. Technical indicators are bullish overall, with the price above key support at $205. Recent news includes a product launch of 'Editions' for its supply chain solutions but also an ongoing legal investigation into fiduciary duties by Rosen Law Firm.
The outlook is positive given earnings momentum and analyst consensus, but risks include the legal overhang and a high P/E ratio of 59.26 suggesting premium valuation. Upside to the high target of $260 exists if execution remains strong, though investors should weigh growth prospects against valuation and litigation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
